Clinical Scorecard: Impact of Lewy Body Co-Pathology on Clinical and Imaging Characteristics in Amnestic Patients
At a Glance
Category
Detail
Condition
Alzheimer’s disease (AD) with Lewy body (LB) co-pathology and pure LB pathology in amnestic patients
Key Mechanisms
Co-occurrence of amyloid-β and tau pathology with α-synuclein Lewy bodies affecting neurodegeneration patterns and cognitive profiles
Target Population
Patients clinically diagnosed with amnestic mild cognitive impairment (aMCI) or AD dementia (ADD)
Care Setting
Specialized neuroimaging and biomarker assessment centers, memory clinics
Key Highlights
LB co-pathology in AD is associated with more severe hypometabolism and faster cognitive decline but does not alter the typical temporo-parietal hypometabolic pattern or memory-predominant cognitive profile.
Patients with relatively pure LB pathology exhibit a dysexecutive and visuospatial cognitive profile with a distinct posterior-occipital hypometabolism pattern characteristic of Lewy body disease.
Presence of LB pathology increases risk of hallucinations, especially in patients showing posterior-occipital hypometabolism, with a hazard ratio of 2.58 compared to AD-typical patterns.
Guideline-Based Recommendations
Diagnosis
Use CSF biomarkers (amyloid-β1–42, p-tau181) and α-synuclein seed amplification assay to classify patients into AD and LB pathology groups.
Employ FDG-PET imaging to identify characteristic hypometabolic patterns: temporo-parietal for AD and posterior-occipital for LB pathology.
Consider APOE4 genotype status as supportive but not definitive for distinguishing AD with or without LB co-pathology.
Management
Monitor cognitive decline trajectories closely in patients with LB co-pathology due to faster progression.
Tailor clinical management recognizing distinct cognitive profiles: memory-predominant in AD+LB+ and AD+LB−, dysexecutive/visuospatial in AD−LB+.
Anticipate and manage neuropsychiatric symptoms such as hallucinations, especially in patients with LB-like hypometabolic patterns.
Monitoring & Follow-up
Longitudinal cognitive assessments focusing on memory, executive function, and visuospatial abilities.
Regular neuroimaging follow-up with FDG-PET to monitor progression of hypometabolic patterns.
Surveillance for development of hallucinations and other neuropsychiatric symptoms.
Risks
Faster cognitive decline in AD patients with LB co-pathology.
Higher risk of hallucinations in patients exhibiting posterior-occipital hypometabolism.
Potential misdiagnosis due to overlapping clinical features between AD and LB pathology.
Patient & Prescribing Data
Amnestic patients with clinical diagnoses of aMCI or AD dementia, stratified by presence of LB co-pathology.
Recognition of LB co-pathology may inform prognosis and guide symptomatic management, particularly addressing neuropsychiatric symptoms and cognitive decline rates.
Clinical Best Practices
Incorporate multimodal biomarker assessment including CSF and FDG-PET to improve diagnostic accuracy.
Differentiate cognitive profiles to tailor patient counseling and management strategies.
Monitor for neuropsychiatric symptoms proactively, especially hallucinations in patients with LB pathology.
Use APOE4 genotype status as an adjunctive tool but not sole determinant in diagnosis.
Recognize that LB co-pathology modifies disease progression without altering core AD hypometabolic patterns.
by Jesús Silva-Rodríguez, Miguel A Labrador-Espinosa, Linda Zhang, Sandra Castro-Labrador, Francisco Javier López-González, Alexis Moscoso, Pascual Sánchez-Juan, Michael Schöll, Michel J Grothe, for the Alzheimer’s Disease Neuroimaging Initiative
